SCHEMBL23836636

SCHEMBL23836636

O=c1ccn(C2OC(CO)C(O)C2O)c(=O)n1CCc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 3/20 0.47
▸ SLC28A1 O00337 1/20 0.47
▸ SLC28A2 O43868 1/20 0.47
▸ SLC28A3 Q9HAS3 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ MTOR P42345 1/20 0.46
▸ MDM2 Q00987 1/20 0.46
▸ NCOA1 Q15788 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ ADORA2A P29274 2/20 0.45
▸ ADORA2B P29275 1/20 0.45
▸ ADORA3 P0DMS8 1/20 0.45
▸ ADORA1 P30542 1/20 0.45
▸ SLC5A2 P31639 2/20 0.44
▸ MAPT P10636 1/20 0.43
▸ CDA P32320 1/20 0.43
▸ PYGM P11217 1/20 0.40
▸ P2RY6 Q15077 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16138518 1.00 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL16310898 1.00 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL19464944 1.00 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL19807501 1.00 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL19807372 0.89 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL21658577 0.89 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL16311135 0.89 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL19807415 0.89 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL19464871 0.89 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA
SCHEMBL16311131 0.89 SLC29A1 (0.47) SLC29A1SLC28A1SLC28A2SLC28A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165887-A1 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-06-01 — — US disclosed
US-11124536-B2 Uridine nucleoside derivatives, compositions and methods of use TUFTS UNIVERSITY (US) 2021-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11124536-B2 Uridine nucleoside derivatives, compositions and methods of use P2RY6, UPP1, UMPS SLC29A1 54/4885SLC28A1 159/4885SLC28A2 85/4885
US-20230165887-A1 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS TNNI3, CPT1B, TNNT2 SLC29A1 2267/4885SLC28A1 1459/4885SLC28A2 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback